10 patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of radiocontrast induced nephropathy clinical evaluation,” Journal of the American College of Cardiology, vol. 33, p. 403, 1999. [58] A. J. Taylor, D. Hotchkiss, R. W. Morse, and J. McCabe, “PREPARED: preparation for angiography in renal dysfunc- tion: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction,” Chest, vol. 114, no. 6, pp. 1570–1574, 1998. [59] H. S. Trivedi, H. Moore, S. Nasr et al., “A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity,” Nephron Clinical Practice, vol. 93, no. 1, pp. C29–C34, 2003. [60] C. Mueller, G. Buerkle, H. J. Buettner et al., “Prevention of contrast media-associated nephropathy: randomized com- parison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty,” Archives of Internal Medicine, vol. 162, no. 3, pp. 329–336, 2002. [61] F. Stacul, A. Adam, C. R. Becker et al., “Strategies to reduce the risk of contrast-induced nephropathy,” American Journal of Cardiology, vol. 98, no. 6, pp. 59–77, 2006. [62] C. Briguori, F. Airoldi, D. D’Andrea et al., “Renal insuﬃ- ciency following contrast media administration trial (REME- DIAL): a randomized comparison of 3 preventive strategies,” Circulation, vol. 115, no. 10, pp. 1211–1217, 2007. [63] A. Recio-Mayoral, M. Chaparro, B. Prado et al., “The reno- protective eﬀect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percuta- neous coronary intervention: the RENO Study,” Journal of the American College of Cardiology, vol. 49, no. 12, pp. 1283– 1288, 2007. [64] G. J. Merten, W. P. Burgess, L. V. Gray et al., “Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 19, pp. 2328–2334, 2004. [65] A. Bouzas-Mosquera and A. Recio-Mayoral, “Sodium bicar- bonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy,” American Heart Journal, vol. 155, no. 4, article no. e31, 2008. [66] D. Castini, S. Lucreziotti, L. Bosotti et al., “Prevention of contrast-induced nephropathy: a single center randomized study,” Clinical Cardiology, vol. 33, no. 3, pp. E63–E68, 2010. [67] E. E. Ozcan, S. Guneri, B. Akdeniz et al., “Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial,” American Heart Journal, vol. 154, no. 3, pp. 539–544, 2007. [68] A. Vasheghani-Farahani, G. Sadigh, S. E. Kassaian et al., “Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial,” Journal of Nephrology, vol. 23, p. 216, 2010. [69] A. Vasheghani-Farahani, G. Sadigh, S. E. Kassaian et al., “sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial ,” American Journal of Kidney Diseases, vol. 54, no. 4, pp. 610–618, 2009. [70] V. Kunadian, A. Zaman, I. Spyridopoulos, and W. Qiu, “Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials,” European Journal of Radiology. In press. Cardiology Research and Practice [71] S. D. Navaneethan, S. Singh, S. Appasamy, R. E. Wing, and A. R. Sehgal, “Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 53, no. 4, pp. 617–627, 2009. [72] S. Zoungas, T. Ninomiya, R. Huxley et al., “Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy,” Annals of Internal Medicine, vol. 151, no. 9, pp. 631–638, 2009. [73] L. C. Clavijo, T. L. Pinto, P. K. Kuchulakanti et al., “Eﬀect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients,” American Journal of Cardiology, vol. 97, no. 7, pp. 981–983, 2006. [74] J. DiMari, J. Megyesi, N. Udvarhelyi, P. Price, R. Davis, and R. Saﬁrstein, “N-acetyl cysteine ameliorates ischemic renal failure,” American Journal of Physiology, vol. 272, no. 3, pp. F292–F298, 1997. [75] M. Tepel, M. Van Der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek, “Prevention of radiographic- contrast-agent-induced reductions in renal function by acetylcysteine,” New England Journal of Medicine, vol. 343, no. 3, pp. 180–184, 2000. [76] L. J. Diaz-Sandoval, B. D. Kosowsky, and D. W. Losordo, “Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial),” American Journal of Cardiology, vol. 89, no. 3, pp. 356–358, 2002. [77] A. D. Azmus, C. Gottschall, A. Manica et al., “Eﬀectiveness of acetylcysteine in prevention of contrast nephropathy,” Journal of Invasive Cardiology, vol. 17, no. 2, pp. 80–84, 2005. [78] G. Marenzi, E. Assanelli, I. Marana et al., “N-acetylcysteine and contrast-induced nephropathy in primary angioplasty,” New England Journal of Medicine, vol. 354, no. 26, pp. 2773– 2782, 2006. [79] J. Kay, W. H. Chow, T. M. Chan et al., “Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 5, pp. 553–558, 2003. [80] J. G. Webb, G. E. Pate, K. H. Humphries et al., “A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of eﬀect,” American Heart Journal, vol. 148, no. 3, pp. 422–429, 2004. [81] F. Boccalandro, M. Amhad, R. W. Smalling, and S. Sdringola, “Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic con- trast,” Catheterization and Cardiovascular Interventions, vol. 58, no. 3, pp. 336–341, 2003. [82] C. Briguori, F. Manganelli, P. Scarpato et al., “Acetylcysteine and contrast agent-associated nephrotoxicity,” Journal of the American College of Cardiology, vol. 40, no. 2, pp. 298–303, 2002. [83] C. Briguori, A. Colombo, A. Violante et al., “Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity,” European Heart Journal, vol. 25, no. 3, pp. 206–211, 2004. [84] C. S. R. Baker, A. Wragg, S. Kumar, R. De Palma, L. R. I. Baker, and C. J. Knight, “A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study,” Journal of the American College of Cardiology, vol. 41, no. 12, pp. 2114–2118, 2003. [85] B. K. Nallamothu, K. G. Shojania, S. Saint et al., “Is acetylcys- teine eﬀective in preventing contrast-related nephropathy? A